Et al Phillip Frost MD - 09 Jan 2026 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Role: Director, 10%+ Owner
Signature: /s/ Phillip Frost, MD ET AL
Issuer symbol: COCP
Transactions as of: 09 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 13 Jan 2026, 16:10:05 UTC
Previous filing: 02 Jan 2026
Next filing: 09 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
FROST PHILLIP MD ET AL	Director, 10%+ Owner	4400 BISCAYNE BLVD, MIAMI	/s/ Phillip Frost, MD ET AL	13 Jan 2026	0000898860

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	COCP	Stock Options (Right to Buy)	Award	$0	+24,615		$0.000000	24,615	09 Jan 2026	Common Stock	24,615	$1.10	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Content

The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Remarks:

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.